SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-117678
Filing Date
2023-11-14
Accepted
2023-11-14 07:35:30
Documents
13
Period of Report
2023-11-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2330690d1_8k.htm   iXBRL 8-K 25670
2 EXHIBIT 99.1 tm2330690d1_ex99-1.htm EX-99.1 88055
  Complete submission text file 0001104659-23-117678.txt   298894

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA bcli-20231114.xsd EX-101.SCH 3036
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE bcli-20231114_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bcli-20231114_pre.xml EX-101.PRE 22373
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2330690d1_8k_htm.xml XML 3323
Mailing Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019
Business Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019 201-488-0460
BRAINSTORM CELL THERAPEUTICS INC. (Filer) CIK: 0001137883 (see all company filings)

IRS No.: 207273918 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36641 | Film No.: 231401598
SIC: 2836 Biological Products, (No Diagnostic Substances)